First human doses given in early drug safety test
NCT ID NCT05501717
Summary
This early-stage study aims to check the safety and side effects of a single dose of an experimental drug called ALXN2030 in healthy people. It will involve 48 healthy adult volunteers, with some receiving the drug and others receiving a placebo. Researchers will measure how the drug moves through the body and how the immune system reacts to it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Harrow, HA1 3UJ, United Kingdom
Conditions
Explore the condition pages connected to this study.